RBC Capital cuts Intra-Cellular stock rating, hikes target to $132
RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...
Dana and Jack Larsen: What It’s Like Working in Wealth Management With Our Dad
Many people deliberately chart different career paths from their parents, but not siblings Dana and Jack Larsen. Working with ...
RBC Capital highlights strong earnings momentum as Richemont shares see price target boost
RBC Capital Markets updated its outlook on Compagnie Financiere Richemont SA (JO:CFRJ) (CFR:SW) (OTC: CFRUY), increasing the ...